A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure - New England Journal of Medicine - 2001

Brief Summary:

In a time when HFrEF therapy included ACE inhibitors but not beta blockers, addition of valsartan to standard HFrEF therapy did not improve survival but reduced the incidence of the composite endpoint of morbidity and mortality, largely through a decrease in HF hospitalizations.